NCT06893302 Impact of Bone-Marrow Aspirate Injections in Knee Arthroscopy
| NCT ID | NCT06893302 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital for Special Surgery, New York |
| Condition | Chondral Lesion of the Knee |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-02-03 |
| Primary Completion | 2029-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-02-03 with a primary completion date of 2029-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will examine whether using bone marrow aspirate (BMA) during knee arthroscopy surgery can improve patient outcomes. The investigators will enroll 50 patients who need knee arthroscopy surgery for meniscus injuries or cartilage damage. Like flipping a coin, patients will be randomly assigned to one of two groups of 25 patients each. One group will receive standard arthroscopic surgery plus an injection of bone marrow aspirate, while the other group will receive standard surgery plus a saline (salt water) injection. During surgery, for patients in the treatment group, approximately 4mL (less than one teaspoon) of bone marrow will be taken from their hip bone using a special needle system. A small amount (1mL) will be sent to the laboratory for testing. Patients will be followed for 12 months after surgery and will complete questionnaires about their pain levels and knee function at several time points: before surgery, 2 weeks, 6 weeks, 3 months, 6 months, and 12 months after surgery. These questionnaires will ask about pain, daily activities, and overall improvement.
Eligibility Criteria
Inclusion Criteria: 1. Require a primary knee arthroscopy for a meniscal injury or focal chondral defect (knee debridement or meniscectomy) 2. Have Kellgren-Lawrence grade 0 arthritis 3. Have Outerbridge cartilage grade 2 or lower 4. Ages 18-64 Exclusion Criteria: 1. Have previously undergone ipsilateral knee surgery 2. Have Kellegren-Lawrence grade 3 or greater 3. Have received other OrthoBiologics within 3 mo of surgery 4. Have ligament deficiencies 5. Need meniscal repair 6. Need a concomitant osteotomy or other realignment surgery 7. Have used DMARDs within the last three months 8. Have a hx of anemia, bleeding disorders, or inflammatory joint disease (rheumatoid arthritis, infectious arthritis, hemophilic arthropathy, Charcot's knee) 9. Have a hx of metabolic bone disease (osteoporosis, osteomalacia, rickets, osteitis fibrosa cystica, Paget's disease of bone) 10. Patients who are currently pregnant
Contact & Investigator
Anil S Ranawat, MD
PRINCIPAL INVESTIGATOR
Hospital for Special Surgery, New York
Frequently Asked Questions
Who can join the NCT06893302 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 64 Years, studying Chondral Lesion of the Knee. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06893302 currently recruiting?
Yes, NCT06893302 is actively recruiting participants. Contact the research team at raghurama@hss.edu for enrollment information.
Where is the NCT06893302 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06893302 clinical trial?
NCT06893302 is sponsored by Hospital for Special Surgery, New York. The principal investigator is Anil S Ranawat, MD at Hospital for Special Surgery, New York. The trial plans to enroll 50 participants.